BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 27356959)

  • 1. Targeting choline phospholipid metabolism: GDPD5 and GDPD6 silencing decrease breast cancer cell proliferation, migration, and invasion.
    Cao MD; Cheng M; Rizwan A; Jiang L; Krishnamachary B; Bhujwalla ZM; Bathen TF; Glunde K
    NMR Biomed; 2016 Aug; 29(8):1098-107. PubMed ID: 27356959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Effects of Doxorubicin on Choline Metabolism in Breast Cancer.
    Cheng M; Rizwan A; Jiang L; Bhujwalla ZM; Glunde K
    Neoplasia; 2017 Aug; 19(8):617-627. PubMed ID: 28654865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancer.
    Cao MD; Döpkens M; Krishnamachary B; Vesuna F; Gadiya MM; Lønning PE; Bhujwalla ZM; Gribbestad IS; Glunde K
    NMR Biomed; 2012 Sep; 25(9):1033-42. PubMed ID: 22279038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Silencing of the glycerophosphocholine phosphodiesterase GDPD5 alters the phospholipid metabolite profile in a breast cancer model in vivo as monitored by (31) P MRS.
    Wijnen JP; Jiang L; Greenwood TR; Cheng M; Döpkens M; Cao MD; Bhujwalla ZM; Krishnamachary B; Klomp DW; Glunde K
    NMR Biomed; 2014 Jun; 27(6):692-9. PubMed ID: 24764256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of breast cancer cell growth and invasiveness by dual silencing of HER-2 and VEGF.
    Tai W; Qin B; Cheng K
    Mol Pharm; 2010 Apr; 7(2):543-56. PubMed ID: 20047302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GDPD5 is a glycerophosphocholine phosphodiesterase that osmotically regulates the osmoprotective organic osmolyte GPC.
    Gallazzini M; Ferraris JD; Burg MB
    Proc Natl Acad Sci U S A; 2008 Aug; 105(31):11026-31. PubMed ID: 18667693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interplay of choline metabolites and genes in patient-derived breast cancer xenografts.
    Grinde MT; Skrbo N; Moestue SA; Rødland EA; Borgan E; Kristian A; Sitter B; Bathen TF; Børresen-Dale AL; Mælandsmo GM; Engebraaten O; Sørlie T; Marangoni E; Gribbestad IS
    Breast Cancer Res; 2014 Jan; 16(1):R5. PubMed ID: 24447408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Silencing of the annexin II gene down-regulates the levels of S100A10, c-Myc, and plasmin and inhibits breast cancer cell proliferation and invasion.
    Zhang J; Guo B; Zhang Y; Cao J; Chen T
    Saudi Med J; 2010 Apr; 31(4):374-81. PubMed ID: 20383413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy.
    Osta WA; Chen Y; Mikhitarian K; Mitas M; Salem M; Hannun YA; Cole DJ; Gillanders WE
    Cancer Res; 2004 Aug; 64(16):5818-24. PubMed ID: 15313925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth.
    Keller M; Rohlf K; Glotzbach A; Leonhardt G; Lüke S; Derksen K; Demirci Ö; Göçener D; AlWahsh M; Lambert J; Lindskog C; Schmidt M; Brenner W; Baumann M; Zent E; Zischinsky ML; Hellwig B; Madjar K; Rahnenführer J; Overbeck N; Reinders J; Cadenas C; Hengstler JG; Edlund K; Marchan R
    J Exp Clin Cancer Res; 2023 Jan; 42(1):25. PubMed ID: 36670508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The siRNA-mediated silencing of Bmi-1 promotes apoptosis and inhibits invasion of MCF-7 breast cancer cells].
    Deng X; Wu X; Weng H; Song F
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Aug; 32(8):1036-40. PubMed ID: 27412932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silencing of ANXA3 expression by RNA interference inhibits the proliferation and invasion of breast cancer cells.
    Zhou T; Li Y; Yang L; Liu L; Ju Y; Li C
    Oncol Rep; 2017 Jan; 37(1):388-398. PubMed ID: 27878264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic inhibition of aggressive breast cancer cell migration and invasion by cytoplasmic delivery of anti-RhoC silencing RNA and presentation of EPPT1 peptide on "smart" particles.
    Kaushal N; Tiruchinapally G; Durmaz YY; Bao L; Gilani R; Merajver SD; ElSayed MEH
    J Control Release; 2018 Nov; 289():79-93. PubMed ID: 30149048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EDI3 links choline metabolism to integrin expression, cell adhesion and spreading.
    Lesjak MS; Marchan R; Stewart JD; Rempel E; Rahnenführer J; Hengstler JG
    Cell Adh Migr; 2014; 8(5):499-508. PubMed ID: 25482527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Silencing ARHGAP9 correlates with the risk of breast cancer and inhibits the proliferation, migration, and invasion of breast cancer.
    Wang T; Ha M
    J Cell Biochem; 2018 Sep; 119(9):7747-7756. PubMed ID: 29905031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Knockdown of CART1 induces S phase arrest and inhibits invasion and migration of MDA-MB-231 breast cancer cells].
    Guan T; Su L; Yi Y
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Apr; 32(4):474-8. PubMed ID: 27053613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "Smart" Nanoparticles Enhance the Cytoplasmic Delivery of Anti-RhoC Silencing RNA and Inhibit the Migration and Invasion of Aggressive Breast Cancer Cells.
    Kaushal N; Durmaz YY; Bao L; Merajver SD; ElSayed ME
    Mol Pharm; 2015 Jul; 12(7):2406-17. PubMed ID: 26020100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymeric Delivery of siRNA against Integrin-β1 (CD29) to Reduce Attachment and Migration of Breast Cancer Cells.
    Meenakshi Sundaram DN; Kucharski C; Parmar MB; Kc RB; Uludağ H
    Macromol Biosci; 2017 Jun; 17(6):. PubMed ID: 28160423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Choline-releasing glycerophosphodiesterase EDI3 drives tumor cell migration and metastasis.
    Stewart JD; Marchan R; Lesjak MS; Lambert J; Hergenroeder R; Ellis JK; Lau CH; Keun HC; Schmitz G; Schiller J; Eibisch M; Hedberg C; Waldmann H; Lausch E; Tanner B; Sehouli J; Sagemueller J; Staude H; Steiner E; Hengstler JG
    Proc Natl Acad Sci U S A; 2012 May; 109(21):8155-60. PubMed ID: 22570503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of RhoGDIα increased migration and invasion of ER (+) MCF7 and ER (-) MDA-MB-231 breast cancer cells.
    Hooshmand S; Ghaderi A; Yusoff K; Karrupiah T; Rosli R; Mojtahedi Z
    Cell Adh Migr; 2013; 7(3):297-303. PubMed ID: 23563506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.